At a glance
- Originator SSP Co
- Developer Arena Pharmaceuticals; SSP Co
- Class Neuroprotectants; Nootropics
- Mechanism of Action Acetylcholinesterase inhibitors; Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 11 Mar 2022 Arena Pharmaceuticals has been acquired and merged into Pfizer
- 24 Apr 2002 Discontinued - Phase-II for Alzheimer's disease in USA (PO)
- 24 Apr 2002 Discontinued - Preclinical for Alzheimer's disease in Japan (unspecified route)